Literature DB >> 2438445

Generation of cell types with myoepithelial and mesenchymal phenotypes during the conversion of rat mammary tumor epithelial stem cells into elongated cells.

M J Warburton, S A Ferns, C M Hughes, C H Sear, P S Rudland.   

Abstract

Epithelial cell lines isolated from benign rat mammary tumors converted to elongated cells that showed some aspects of myoepithelial differentiation. This cellular conversion was blocked in cells isolated from malignant tumors. For investigation of the pathway of the conversion, a rat mammary epithelial cell line (Rama 25) that converted to elongated cells through a series of morphologically distinct intermediates was isolated. These intermediates formed a series in the order: Rama 25, Rama 25-I2, Rama 25-I1, Rama 25-I4, and elongated cells. These cell lines were examined for aspects of myoepithelial or mesenchymal differentiation with the use of a polyclonal antibody to type IV collagen and a keratin monoclonal antibody, LP34 (myoepithelial markers), or a polyclonal antibody to type I procollagen (mesenchymal marker) for cells grown on plastic or as tumors in nude mice. The more epithelial-like cell lines Rama 25 and Rama 25-I2 produced relatively small amounts of type IV collagen and did not stain with LP34 or anti-type I procollagen. The flatter, polygonal cell line Rama 25-I1 stained more strongly with the antibody to type IV collagen but did not stain with anti-type I procollagen. Rama 25-I1 cells, and to a lesser extent Rama 25-I4 cells in tumors, contained a network of cytoplasmic filaments that stained strongly with LP34. The elongated cells, Rama 25-I4 and Rama 25-floaters (Rama 25-FL), did not stain with LP34 in vitro but produced an extracellular matrix that stained with antibodies to both type I procollagen and type IV collagen. The results obtained with these marker proteins suggested that, in this series of morphologic intermediates, the myoepithelial phenotype was best expressed in Rama 25-I1 cells and to a lesser extent in 25-I4 cells. However, this phenotype was relatively unstable, converting to elongated cells, some of which have decreased myoepithelial and increased mesenchymal characteristics. Such a pathway may explain the mixed population of cells seen in some types of benign mammary tumor.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2438445

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  7 in total

1.  Characterization of human mammary cell types in primary culture: immunofluorescent and immunocytochemical indicators of cellular heterogeneity.

Authors:  P S Rudland; C M Hughes; S A Ferns; M J Warburton
Journal:  In Vitro Cell Dev Biol       Date:  1989-01

2.  Distinction between vascular smooth muscle cells and myoepithelial cells in primary monolayer cultures of human breast tissue.

Authors:  O W Petersen; B Van Deurs
Journal:  In Vitro Cell Dev Biol       Date:  1989-03

3.  Enhanced expression of type 1 procollagen and transforming growth factor-beta in tuberculin induced delayed type hypersensitivity.

Authors:  A Wangoo; H T Cook; G M Taylor; R J Shaw
Journal:  J Clin Pathol       Date:  1995-04       Impact factor: 3.411

4.  Increased inflammatory cytokines and new collagen formation in cutaneous tuberculosis and sarcoidosis.

Authors:  B G Marshall; A Wangoo; H T Cook; R J Shaw
Journal:  Thorax       Date:  1996-12       Impact factor: 9.139

5.  Type 1 procollagen as a marker of severity of scarring after sternotomy: effects of topical corticosteroids.

Authors:  Y Riaz; H T Cook; A Wangoo; B Glenville; R J Shaw
Journal:  J Clin Pathol       Date:  1994-10       Impact factor: 3.411

6.  Characterization of four in vitro established canine mammary carcinoma and one atypical benign mixed tumor cell lines.

Authors:  E Hellmén
Journal:  In Vitro Cell Dev Biol       Date:  1992-05

Review 7.  Differentiation of mammary stem cells in vivo and in vitro.

Authors:  R Barraclough; P S Rudland
Journal:  Environ Health Perspect       Date:  1989-03       Impact factor: 9.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.